Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cormedix Inc
(NQ:
CRMD
)
4.930
-0.230 (-4.45%)
Streaming Delayed Price
Updated: 12:20 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cormedix Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Why Cormedix (CRMD) Stock Is Getting Hammered
June 29, 2023
CorMedix Inc. (NASDAQ: CRMD) shares are trading lower by 23.27% to $3.89 Thursday morning after the company priced its public offering of 7.5 million shares at $4 per share and pre-funded warrants to...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 29, 2023
Via
Benzinga
Why CorMedix Are Trading Lower By 22%; Here Are 20 Stocks Moving Premarket
June 29, 2023
Gainers Eco Wave Power Global AB (NASDAQ: WAVE) shares surged 123% to $3.48 in pre-market trading after dropping over 8% on Wednesday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
June 29, 2023
We're starting Thursday with a detailed look at all of the biggest pre-market stock movers worth keeping an eye on today!
Via
InvestorPlace
Analyst Ratings for Cormedix
June 21, 2023
Analysts have provided the following ratings for Cormedix (NASDAQ:CRMD) within the last quarter:
Via
Benzinga
What 5 Analyst Ratings Have To Say About Cormedix
May 16, 2023
Via
Benzinga
CorMedix (CRMD) Q1 2023 Earnings Call Transcript
May 15, 2023
CRMD earnings call for the period ending March 31, 2023.
Via
The Motley Fool
As CorMedix's DefenCath Moves Forward On Regulatory Path, Analyst Boosts Price Target
May 19, 2023
Tuesday, CorMedix Inc (NASDAQ: CRMD) resubmitted New Drug Application for DefenCath to the FDA, and the submission has been acknowledged as
Via
Benzinga
Recap: Cormedix Q1 Earnings
May 15, 2023
Via
Benzinga
Preview: Cormedix's Earnings
May 12, 2023
Via
Benzinga
Citius Pharmaceuticals Approaches End Of Trial For Catheter-Related Bloodstream Infections – How Are Analysts Scoring Its Stock?
May 04, 2023
The late-stage biopharma Citius Pharmaceuticals Inc. (NASDAQ: CTXR) is approaching the conclusion of the phase 3 trial for its drug, Mino-Lok.
Via
Benzinga
7 Small-Cap Biotech Stocks with Massive Potential
April 27, 2023
Although small-cap biotech stocks present high risks, if they hit one out of the park, the rewards can be astronomical.
Via
InvestorPlace
7 Biotech Stocks With Huge Return Potential for Long-Term Investors
April 26, 2023
Although a wildly speculative sector, the low-cost, high-potential biotech stocks to buy and hold may deliver the goods for gamblers.
Via
InvestorPlace
Expert Ratings for Cormedix
March 31, 2023
Via
Benzinga
Cormedix's Return On Capital Employed Overview
March 31, 2023
Via
Benzinga
A Preview Of Cormedix's Earnings
March 29, 2023
Via
Benzinga
Cormedix's Return On Capital Employed Insights
December 20, 2022
Via
Benzinga
Recap: Cormedix Q2 Earnings
August 11, 2022
Cormedix (NASDAQ:CRMD) reported its Q2 earnings results on Thursday, August 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
April 11, 2023
A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global...
Via
Benzinga
CorMedix Inc Common Stock (CRMD) Q3 2022 Earnings Call Transcript
November 10, 2022
CRMD earnings call for the period ending September 30, 2022.
Via
The Motley Fool
CorMedix Inc. (NASDAQ:CRMD) Shareholder Alert: Investigation over Potential Wrongdoing
November 04, 2022
San Diego, CA -- (SBWIRE) -- 11/04/2022 -- Certain directors of CorMedix Inc. are under investigation over potential breaches of fiduciary duties.
Via
SBWire
CorMedix Inc. (NASDAQ:CRMD) Shareholder Notice: Update in Lawsuit Announced
September 21, 2022
San Diego, CA -- (SBWIRE) -- 09/21/2022 -- An update was announced in the lawsuit that is pending for certain investors in shares of CorMedix Inc. (NASDAQ:CRMD).
Via
SBWire
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
August 31, 2022
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
Via
Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,100 Today
August 16, 2022
Cormedix (NASDAQ:CRMD) has outperformed the market over the past 10 years by 2.86% on an annualized basis producing an average annual return of 14.54%. Currently, Cormedix has a market capitalization...
Via
Benzinga
Dow Drops Over 100 Points; Verona Pharma Shares Jump
August 09, 2022
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 100 points on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
August 09, 2022
Via
Benzinga
Nasdaq Tumbles 1.5%; BBQ Holdings Shares Spike Higher
August 09, 2022
U.S. stocks traded lower midway through trading, with the Nasdaq dropping around 1.5% on Tuesday.
Via
Benzinga
Why U.S. Stocks Are Trading Mixed; Labor Costs Increase Higher-Than-Expected In Q2
August 09, 2022
U.S. stocks traded mixed this morning, with the Nasdaq dropping around 90 points on Tuesday.
Via
Benzinga
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
August 10, 2022
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.
Via
Benzinga
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session
August 09, 2022
Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD....
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.